Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,934,040
  • Shares Outstanding, K 187,698
  • Annual Sales, $ 1,962 M
  • Annual Income, $ -610,310 K
  • EBIT $ -791 M
  • EBITDA $ -715 M
  • 60-Month Beta 0.32
  • Price/Sales 21.89
  • Price/Cash Flow N/A
  • Price/Book 16.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.01
  • Most Recent Earnings $-1.15 on 11/01/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.89
  • Number of Estimates 6
  • High Estimate -0.77
  • Low Estimate -1.06
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -11.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
211.77 +8.01%
on 11/17/23
228.96 -0.10%
on 12/13/23
+15.54 (+7.29%)
since 11/13/23
3-Month
206.00 +11.04%
on 09/21/23
228.96 -0.10%
on 12/13/23
+22.80 (+11.07%)
since 09/13/23
52-Week
123.77 +84.81%
on 12/28/22
228.96 -0.10%
on 12/13/23
+94.68 (+70.63%)
since 12/13/22

Most Recent Stories

More News
Pfizer Raises Forecast on Robust Drug Sales, Offsets COVID-19 Revenue Decline

Pfizer (PFE) raised its annual profit forecast, driven by robust sales in its cancer and heart disease drug segments, particularly benefiting from its recent acquisition of Seagen. The pharmaceutical giant...

SGEN : 228.74 (-0.07%)
BNTX : 109.54 (-1.74%)
JPM : 220.15 (-1.25%)
Pfizer: From pandemic hero to investor jitters

Pfizer's transitions from pandemic success to market concerns: analyzing revenue stagnation, investor reactions, and the company's strategic roadmap for growth.

PFE : 27.81 (-1.00%)
SGEN : 228.74 (-0.07%)
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.

MRK : 101.62 (-0.26%)
PFE : 27.81 (-1.00%)
SGEN : 228.74 (-0.07%)
This High-Yield Dividend Stock Is a Proven Wealth Creator

This heavily sold-off pharma stock is a bargain.

SGEN : 228.74 (-0.07%)
PFE : 27.81 (-1.00%)
Seattle Genetics: Q3 Earnings Snapshot

Seattle Genetics: Q3 Earnings Snapshot

SGEN : 228.74 (-0.07%)
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

The venerable pharmaceutical companies' shares have slumped this year.

BMY : 55.24 (+1.69%)
SGEN : 228.74 (-0.07%)
REGN : 830.93 (-1.50%)
BNTX : 109.54 (-1.74%)
PFE : 27.81 (-1.00%)
RHHBY : 39.5287 (+0.68%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

/PRNewswire/ -- USA News Group - According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic...

ONC.TO : 1.62 (-2.41%)
BNTX : 109.54 (-1.74%)
ONCY : 1.1600 (-1.69%)
SGEN : 228.74 (-0.07%)
MYGN : 17.86 (-0.72%)
ILMN : 154.57 (+3.21%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

ONCY : 1.1600 (-1.69%)
ONC.TO : 1.62 (-2.41%)
SGEN : 228.74 (-0.07%)
MYGN : 17.86 (-0.72%)
ILMN : 154.57 (+3.21%)
BNTX : 109.54 (-1.74%)
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

ONCY : 1.1600 (-1.69%)
ONC.TO : 1.62 (-2.41%)
GNLX : 3.11 (-3.12%)
CRNX : 57.14 (+0.79%)
PFE : 27.81 (-1.00%)
SGEN : 228.74 (-0.07%)
Navigating the Surge in Pancreatic Cancer: The Innovative Strategies Offering New Hope

USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s...

ONCY : 1.1600 (-1.69%)
ONC.TO : 1.62 (-2.41%)
GNLX : 3.11 (-3.12%)
CRNX : 57.14 (+0.79%)
PFE : 27.81 (-1.00%)
SGEN : 228.74 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries....

See More

Key Turning Points

3rd Resistance Point 229.11
2nd Resistance Point 229.03
1st Resistance Point 228.89
Last Price 228.74
1st Support Level 228.67
2nd Support Level 228.59
3rd Support Level 228.45

See More

52-Week High 228.96
Last Price 228.74
Fibonacci 61.8% 188.78
Fibonacci 50% 176.37
Fibonacci 38.2% 163.95
52-Week Low 123.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar